Dermaesthetic OPD Masterclass

Clinical Recognition

• Core morphology vocabulary: macule, papule, plaque, nodule, vesicle, bulla, pustule, wheal — use this language for every diagnosis for the rest of the course
• Focused history: onset, evolution, triggers, prior treatments tried, itch vs pain, systemic symptoms
• Examination essentials: distribution pattern, symmetry, scalp/nails/mucosa — often the fastest route to diagnosis
• When and how to use dermoscopy as a quick OPD adjunct (pigmented lesions, hair loss, scabies)

Clinical Recognition

• Grading: comedonal (mild) → papulopustular (moderate) → nodulocystic (severe) — grade drives treatment choice
• Distribution clues: jawline/perioral pattern suggests hormonal acne; truncal involvement signals more severe disease

Management — The Exact Blueprint by Grade

Clinical Recognition

• Atrophic patterns: icepick (narrow, deep), boxcar (broad, sharp-edged), rolling (broad, sloping edges)
• Hypertrophic/keloid scarring — more common on the trunk/jawline, raised and firm

Management & Aesthetic Intervention by Scar Type

• Icepick scars: TCA CROSS technique (high-concentration trichloroacetic acid applied focally into the scar) is the most effective single approach; subcision has limited benefit given the narrow, deep tract
• Boxcar scars: combination of subcision (releasing the fibrous tethering base) plus dermal filler for immediate volume, with laser resurfacing or punch excision for deeper, well-defined boxcars
• Rolling scars: subcision is the primary technique — breaking the fibrous bands tethering the scar base to deeper tissue — often combined with microneedling or RF microneedling for overall textural improvement
• Across 3-6 sessions; this should be stated explicitly at the first consultation, not discovered by the patient after one disappointing session

Clinical Recognition

• Subtypes: erythematotelangiectatic (flushing, visible vessels), papulopustular (mimics acne but no comedones), phymatous (skin thickening, classically the nose), ocular rosacea (gritty, red eyes)
• Key differentiator from acne: absence of comedones, presence of background facial erythema and flushing

Management

• Trigger avoidance first — spicy food, alcohol, heat, sun exposure, and topical steroids (which worsen rosacea, a genuinely common iatrogenic trap)
• Papulopustular: topical metronidazole 0.75-1% (Rozex, Metrogyl gel) or azelaic acid 15-20% (Finacea, Azelex); topical ivermectin 1% (Soolantra) as a newer, effective alternative
• Moderate-severe: oral doxycycline at sub-antimicrobial dose (40mg modified-release, or 100mg standard where the MR form isn't available) for its anti-inflammatory rather than antibiotic effect
• Persistent erythema: topical brimonidine gel for same-day vasoconstriction; telangiectasia responds well to vascular laser or IPL

Clinical Recognition

• Atopic dermatitis: flexural distribution, chronic itch-scratch cycle, personal/family atopy history
• Contact dermatitis: sharply demarcated, linked to an identifiable exposure (allergic vs irritant)
• Seborrhoeic dermatitis: greasy scale over the scalp, eyebrows, nasolabial folds — worsens with stress

Management

• Atopic dermatitis: emollients as the daily cornerstone (used liberally, not just during flares); topical corticosteroid by potency matched to site and severity — mild (hydrocortisone 1%) for the face, moderate-potent (mometasone, betamethasone) for the body during flares; tacrolimus 0.03-0.1% (Protopic) or pimecrolimus (Elidel) as steroid-sparing options for the face and flexures; sedating antihistamine at night for itch-driven sleep disruption
• Contact dermatitis: identify and eliminate the allergen/irritant — this is the actual treatment; a short course of topical steroid settles the acute reaction; patch testing for recurrent or unclear cases
• Seborrhoeic dermatitis: ketoconazole 2% shampoo (Nizoral) used on the scalp and washed over the face/chest, or ketoconazole cream for facial involvement; a mild topical steroid for short-term use during flares; zinc pyrithione shampoo as a maintenance option

Clinical Recognition

• Classic plaque psoriasis: well-demarcated, silvery-scaled plaques over extensor surfaces, scalp, umbilicus; nail pitting/onycholysis
• Other patterns: guttate (post-streptococcal, droplet lesions), inverse (flexural, minimal scale), pustular (an urgent variant)

Management

• Limited disease: topical corticosteroid plus a vitamin D analogue, either separately or as a combination product (calcipotriol-betamethasone, e.g. Daivobet) applied once daily
• Scalp involvement: coal tar or salicylic acid shampoo to lift scale, followed by a topical steroid solution/lotion
• Widespread disease: narrowband UVB phototherapy where available
• Moderate-severe or joint-involved disease: methotrexate (7.5-25mg once weekly with folic acid supplementation) is the standard systemic first-line; acitretin as an alternative; biologics are highly effective but carry significant cost and access limitations in most Pakistani practice settings, worth mentioning as an option but not a default recommendation

Clinical Recognition

• The classic '6 Ps': Purple, Polygonal, Pruritic, Papules, Planar (flat-topped), on flexor surfaces of wrists/ankles most classically
• Wickham's striae — fine white lines on the surface of papules, best seen with a drop of oil and a dermoscope
• Mucosal involvement: a lacy, white, reticulate pattern on the buccal mucosa — often asymptomatic and found incidentally, but occasionally erosive and painful
• Nail changes: longitudinal ridging, thinning, and in severe cases pterygium formation (permanent scarring fusion of the proximal nail fold to the nail bed) — a reason not to dismiss nail lichen planus as cosmetic

Management

• Localised cutaneous disease: potent topical corticosteroid (betamethasone, clobetasol) under occlusion if needed
• Widespread or rapidly progressive disease: a short tapering course of oral corticosteroid (prednisolone 0.5mg/kg, tapered over 4-6 weeks)
• Oral erosive lichen planus: topical steroid in an adhesive base (triamcinolone in orabase) or a potent topical steroid mouth rinse
• Antihistamines for itch; screen for and stop any temporally-associated new medication, since drug-induced lichenoid reactions are a genuine and easily missed mimic

Clinical Recognition

• Fitzpatrick skin typing (I-VI) and why it matters more in our patient population than almost anywhere else — most patients fall into Type III-V, with higher post-inflammatory hyperpigmentation risk from any aggressive intervention
• Wood's lamp as a quick OPD tool to differentiate epidermal vs dermal pigment, and to screen for fungal/pigmentary mimics

Clinical Recognition

• Symmetric, blotchy hyperpigmentation — centrofacial, malar, or mandibular patterns
• Classify as epidermal, dermal, or mixed (Wood's lamp accentuation helps guide this)
• Identify drivers: sun exposure, hormonal triggers (pregnancy, OCPs), family history

Management — The Exact Blueprint

• First-line topical: triple combination cream (hydroquinone 4% + tretinoin 0.05% + a mild steroid, e.g. Tri-Luma) applied at night for up to 8 weeks (its licensed course), then step down to hydroquinone alone or a non-hydroquinone maintenance agent
• Non-hydroquinone options for maintenance or hydroquinone-intolerant patients: azelaic acid 20%, tranexamic acid (topical or oral 250mg BD in resistant cases, screened for contraindications), kojic acid, and niacinamide-based combinations
• Adjunct in-office procedures: superficial chemical peels (glycolic, mandelic) or low-fluence Q-switched Nd:YAG toning — always as an ADJUNCT to topical therapy and strict photoprotection, never as a replacement for either
• Non-negotiable throughout treatment: daily broad-spectrum sunscreen, reapplied — melasma treated without genuine sun discipline will not hold its improvement

Clinical Recognition

• PIH follows a clear inflammatory trigger (acne, eczema, trauma) — distribution matches the prior lesion
• Differentiate from melasma (symmetric, no preceding inflammation) and tinea versicolor (fine scale, Wood's lamp fluorescence, KOH positive)

Management

• Treat the underlying inflammatory condition first — PIH will not resolve while the trigger remains active
• Topical: azelaic acid, niacinamide, or a short course of hydroquinone for stubborn cases; retinoids accelerate epidermal turnover and fading
• Strict sun protection — PIH darkens rapidly with UV exposure and this is the single most common reason it fails to fade

Clinical Recognition

• Well-demarcated, depigmented (not hypopigmented) macules/patches; classic sites — face, hands, genitalia, periorificial
• Signs of activity: Koebner phenomenon, confetti-like lesions, trichrome border — important for treatment planning and counselling

Management

• Localised, stable disease: potent topical corticosteroid or topical tacrolimus 0.1% (Protopic), particularly for the face where steroid atrophy risk is higher
• Widespread or active disease: narrowband UVB phototherapy is the standard first-line systemic option where available; oral mini-pulse corticosteroids can arrest rapidly progressive disease
• Camouflage and depigmentation (for extensive, refractory facial disease) are legitimate options to discuss once medical treatment has been given a fair trial

Clinical Recognition

• Androgenetic alopecia: gradual, patterned thinning (frontotemporal/vertex in men, diffuse crown thinning with a preserved frontal line in women)
• Telogen effluvium: diffuse shedding 2-3 months after a triggering event (illness, surgery, postpartum, crash dieting, severe stress)
• Alopecia areata: well-defined, smooth round patches of hair loss, often sudden onset; exclamation-mark hairs at the margin
• Basic work-up to consider: ferritin, thyroid profile, and a directed history for triggers/nutritional status

Management — The Exact Blueprint

Clinical Recognition

• Male-pattern terminal hair growth in women — screen for PCOS and other endocrine causes when associated with irregular cycles, acne, or weight changes

Management

• Address the underlying cause where identified (PCOS management, combined oral contraceptive, spironolactone 50-200mg/day for the androgen-driven component)
• Cosmetic hair removal (laser hair reduction being the most durable option) for direct symptomatic management alongside medical treatment

Clinical Recognition

• Onychomycosis: thickened, discoloured (yellow-brown), crumbly nail plate, usually starting distally; confirm with KOH/culture before committing to months of oral treatment — this is genuinely worth doing, since several look-alike conditions don't need antifungals at all
• Psoriatic nail disease: pitting, onycholysis, oil-drop discolouration, subungual hyperkeratosis — a marker worth specifically linking back to joint-disease screening
• Paronychia: acute (painful, red, swollen, often with pus — usually bacterial) vs chronic (repeated wet work, candida involvement, affects the proximal nail fold over weeks)
• Ingrown toenail (onychocryptosis): lateral nail edge penetrating the surrounding skin, usually the great toe, causing pain and secondary infection

Management

• Onychomycosis: oral terbinafine 250mg/day for 6 weeks (fingernails) or 12 weeks (toenails) is first-line given superior cure rates over topical treatment alone; topical amorolfine or ciclopirox lacquer for mild distal disease or where oral treatment is contraindicated; check LFTs before and during oral terbinafine courses beyond a few weeks
• Chronic paronychia: keep hands dry, avoid prolonged wet work, topical antifungal/steroid combination since candida and low-grade eczema often coexist here
• Acute paronychia: warm soaks, incision and drainage if a clear abscess has formed, oral antibiotics (cloxacillin or cefalexin) if cellulitis is present
• Ingrown toenail: conservative measures (proper trimming technique, cotton wisp elevation) for mild cases; partial nail avulsion with phenolisation of the nail matrix for recurrent cases

Clinical Recognition

• Velvety, hyperpigmented, thickened plaques — classically the neck, axillae, and other flexural areas
• The single most important recognition point: this is a cutaneous marker of insulin resistance, not a primary skin disease — the skin finding should trigger a metabolic work-up, not just a request for a cosmetic fix
• Rapid onset, widespread distribution, or involvement of unusual sites (mucosa, palms) in an adult raises concern for an underlying malignancy (malignant acanthosis nigricans) and warrants prompt further investigation

Management

• Screen for and address the underlying driver: fasting glucose/HbA1c, and in adolescent girls, a PCOS work-up if the clinical picture fits — this is genuinely the treatment, not a cosmetic cream
• Weight management where relevant meaningfully improves the skin findings over time
• Topical retinoids or alpha-hydroxy acids can offer modest cosmetic improvement in texture and pigmentation once the underlying driver is being addressed, but should never be offered as a substitute for the metabolic work-up

Clinical Recognition

• Annular, scaly, advancing-edge plaques with central clearing — classic tinea morphology
• Tinea capitis: scaling with or without patchy alopecia in children — always consider when a child presents with patchy hair loss
• Candidiasis: beefy-red, macerated plaques with satellite pustules in moist, intertriginous areas
• KOH microscopy as a quick, high-yield OPD confirmatory test

Management — The Exact Blueprint

• Tinea corporis/cruris (localised): topical terbinafine 1% or clotrimazole 1%, twice daily for 2-4 weeks — continue for at least a week past visible clearance to prevent early relapse, a genuinely common cause of treatment 'failure'
• Tinea pedis: as above, plus keeping feet dry and treating any concurrent onychomycosis, which otherwise reseeds the skin infection
• Widespread, recurrent, or steroid-modified tinea (tinea incognito, from prior inappropriate steroid use): oral terbinafine 250mg/day for 2-4 weeks, or oral itraconazole as an alternative — note that terbinafine-resistant dermatophytosis (Trichophyton indotineae) is now widespread in South Asia, so itraconazole is often preferred in Pakistan; ask about adherence and prior treatment, and consider mycology if a course fails
• Tinea capitis: ALWAYS requires an oral antifungal — topical treatment alone cannot penetrate the hair follicle; griseofulvin 20mg/kg/day for 6-8 weeks remains a standard, well-tolerated choice in children, with oral terbinafine as a shorter-course alternative
• Candidiasis: topical clotrimazole or nystatin cream for skin; keep the area dry; address contributing factors (diabetes, obesity, incontinence, recent antibiotic use)

Clinical Recognition

• Impetigo: honey-coloured crusted erosions, classically perioral/periorificial in children
• Folliculitis: follicular pustules; cellulitis: spreading erythema, warmth, tenderness, with or without fever; abscess: fluctuant, tender swelling

Management

• Impetigo (localised): topical mupirocin 2% or fusidic acid, three times daily for 5-7 days
• Impetigo (widespread) or folliculitis not responding to topical treatment: oral cephalexin (25-50mg/kg/day) or cloxacillin (50-100mg/kg/day in 4 divided doses) in children, for 7 days
• Cellulitis (uncomplicated, no systemic toxicity): oral cloxacillin or cephalexin for 5-7 days, with a clear review plan if not improving within 48-72 hours
• Abscess: incision and drainage is the primary treatment — antibiotics alone rarely resolve a formed abscess without drainage

Clinical Recognition

• Verrucae: rough, hyperkeratotic papules, often with thrombosed capillary puncta
• Molluscum contagiosum: dome-shaped, umbilicated papules — common in children and immunosuppressed adults
• Herpes simplex: grouped vesicles on an erythematous base, recurrent at the same site
• Herpes zoster: dermatomal, unilateral vesicular eruption — recognise early for antiviral timing

Management

• Verrucae: topical salicylic acid preparations as first-line for home use; cryotherapy in-office for resistant lesions, repeated every 2-3 weeks
• Molluscum: often self-limiting over months and can genuinely be watched in an asymptomatic, cooperative child; curettage or cryotherapy for persistent, spreading, or cosmetically bothersome lesions
• Herpes simplex: oral aciclovir 200mg five times daily or 400mg three times daily (or valaciclovir 500mg BD) for 5 days, started as early as possible in the prodrome/first 72 hours for maximum benefit; suppressive daily therapy for patients with frequent recurrences
• Herpes zoster: oral aciclovir 800mg five times daily (or valaciclovir 1g TDS) for 7 days, ideally started within 72 hours of rash onset; adequate analgesia given the genuine risk of post-herpetic neuralgia

Clinical Recognition

• Scabies: intensely pruritic, worse at night; burrows in finger webs, wrists, genitalia; look for household contacts with similar symptoms
• Pediculosis: visible nits/lice on the scalp or body hair, associated itching

Management

• Scabies: permethrin 5% cream applied neck-to-toe (whole body in infants), left on for 8-12 hours, repeated after 1 week to catch newly-hatched mites; oral ivermectin (200mcg/kg, repeated after 1-2 weeks) as an alternative for extensive disease, crusted scabies, or outbreak settings
• ALL household and close contacts must be treated SIMULTANEOUSLY, symptomatic or not — this is the single most common reason for treatment 'failure,' which is usually reinfestation, not resistance
• Wash all bedding and clothing used in the preceding 3 days in hot water, or seal in a plastic bag for 72 hours if washing isn't practical
• Pediculosis: permethrin 1% shampoo/lotion, or malathion as an alternative; wet-combing with a fine-toothed comb as an adjunct; repeat treatment at day 7-9 to catch newly hatched lice

Clinical Recognition

• Lichen sclerosus: well-demarcated, white, atrophic ('cigarette-paper') plaques, classically in a figure-of-eight pattern around the vulva and perianal area in women, or affecting the glans/foreskin (balanitis xerotica obliterans) in men — itching, soreness, and in men, progressive phimosis are the usual presenting complaints
• Balanitis/balanoposthitis: redness, soreness, and discharge of the glans (with the foreskin in balanoposthitis) — candidal (satellite lesions, common in uncircumcised men and diabetics), irritant/contact, or bacterial causes
• Vulvovaginal candidiasis: itching, soreness, thick white discharge — extremely common and frequently self-diagnosed correctly by patients, though recurrent cases deserve a genuine work-up
• Genital psoriasis: well-demarcated, often less scaly than elsewhere given the moist environment — easily misdiagnosed as a fungal infection if the possibility isn't actively considered

Management

• Lichen sclerosus: ultra-potent topical corticosteroid (clobetasol propionate) is first-line and highly effective if used correctly and for long enough — this is not a condition to under-treat given the genuine risk of scarring and, in longstanding vulvar disease, a small but real increased risk of squamous cell carcinoma, which is why follow-up matters beyond just symptom relief
• Candidal balanitis: topical clotrimazole; treat and screen for diabetes if recurrent, since recurrent candidal balanitis can be the first presenting sign of undiagnosed diabetes in a man with no other symptoms
• Genital psoriasis: a mild-moderate topical steroid, used for shorter courses given the increased absorption in genital skin; avoid the more irritating vitamin D analogues in this location

Clinical Recognition

• Wheals: itchy, raised, evanescent (individual lesions resolve within 24 hours) — the key differentiator from other rashes
• Acute (under 6 weeks) vs chronic spontaneous urticaria (6 weeks or more)
• Angioedema: deeper swelling, often lips/eyelids/tongue — assess airway involvement urgently

Management — The Exact Blueprint

• Acute urticaria: a second-generation, non-sedating antihistamine (cetirizine 10mg, loratadine 10mg, or fexofenadine 180mg) once daily; identify and remove any obvious trigger
• Refractory acute symptoms: updose the same antihistamine up to 4× the standard dose before switching agents — this is standard, evidence-based practice and genuinely under-used in general OPD, where clinicians often switch antihistamines rather than increasing the dose of one that's partially working
• Chronic spontaneous urticaria: updosed second-generation antihistamine as above, given consistently rather than as-needed; refer for consideration of omalizumab if there's no adequate response after 2-4 weeks of updosed antihistamine — a highly effective option where accessible, though cost is a genuine limiting factor in most Pakistani practice settings
• Avoid long-term systemic corticosteroids for chronic urticaria — a short course can settle a severe acute flare, but repeated or prolonged steroid courses are not appropriate maintenance treatment
• Isolated recurrent angioedema without wheals: consider ACE-inhibitor-induced angioedema (stop the drug) and, if truly recurrent and unexplained, hereditary angioedema (C1 esterase inhibitor deficiency) as a differential worth referring for

Clinical Recognition

• Morbilliform/exanthematous drug rash: the most common pattern, widespread maculopapular eruption, usually benign
• Severe cutaneous adverse reactions (SJS/TEN spectrum): mucosal involvement, skin pain, blistering, a positive Nikolsky sign — recognise this distinction immediately

Management

• Morbilliform rash: if the causative drug is not essential, stop it; symptomatic relief with oral antihistamines and, if needed, a short course of a mild-moderate topical steroid; the rash typically fades over 1-2 weeks even without any specific treatment
• SJS/TEN spectrum: STOP the suspected drug immediately — this single action is the most important determinant of outcome and should not wait for a specialist opinion; admit for supportive, burns-unit-style care (fluid/electrolyte management, wound care, infection surveillance); SCORTEN criteria are used by the admitting team to estimate prognosis

Clinical Recognition — Melanoma

• The ABCDE rule for any pigmented lesion: Asymmetry, Border irregularity, Colour variation (multiple shades within one lesion), Diameter over 6mm, Evolving (any change in size, shape, colour, or symptoms — arguably the single most important letter, since it applies regardless of the lesion's size or appearance at any one visit)
• The 'ugly duckling sign': a pigmented lesion that looks different from the patient's other moles is a more reliable real-world screening tool than trying to apply all five ABCDE criteria to every single lesion in a patient with many naevi
• New pigmented lesions after age 40, or any lesion under a nail (subungual, especially with pigment extending onto the surrounding skin — Hutchinson's sign), deserve particular attention

Clinical Recognition — Basal Cell Carcinoma (BCC)

• The most common skin cancer overall; slow-growing, on sun-exposed skin (face is classic)
• Classic appearance: a pearly or translucent papule/nodule with a rolled border and visible telangiectasia over the surface; central ulceration in longstanding lesions gives the traditional 'rodent ulcer' description
• Rarely metastasises, but left untreated causes progressive local tissue destruction — this is a 'don't need to panic, but do need to act' lesion, not an emergency and not something to ignore

Clinical Recognition — Squamous Cell Carcinoma (SCC) & Actinic Keratosis

• Actinic keratosis: the precursor lesion — rough, scaly, erythematous patches on chronically sun-exposed skin, often easier to feel (a sandpaper texture) than to see clearly
• SCC: a scaly, crusted, or ulcerated papule/plaque, growing faster than BCC, with genuinely higher metastatic potential — particularly on the lip and ear, where a lower threshold for biopsy and referral is warranted

Management

• Any lesion meeting ABCDE criteria, showing the ugly duckling sign, or otherwise causing genuine clinical suspicion for melanoma: refer for an EXCISIONAL biopsy with a narrow margin — never a shave biopsy, which can compromise accurate staging (Breslow thickness) if the lesion proves malignant
• Suspected BCC or SCC: biopsy (punch or shave is acceptable here, unlike for suspected melanoma) to confirm before definitive treatment, which is typically surgical excision; Mohs micrographic surgery for high-risk or cosmetically sensitive sites where available
• Actinic keratosis: cryotherapy for isolated lesions; topical 5-fluorouracil or diclofenac gel for field treatment of multiple lesions across a sun-damaged area

Clinical Recognition

Clinical Recognition

• Pemphigus vulgaris: FLACCID bullae that rupture easily, leaving painful erosions; a POSITIVE Nikolsky sign (lateral pressure on normal-appearing skin causes it to shear off); oral mucosal erosions are very often the FIRST presenting sign, sometimes preceding skin lesions by weeks to months — a patient with persistent, unexplained oral erosions deserves this on the differential, not just aphthous ulcers or a viral cause
• Bullous pemphigoid: TENSE bullae (a genuinely useful bedside contrast to pemphigus's flaccid ones), typically in an OLDER patient population, NEGATIVE Nikolsky sign, and comparatively LESS mucosal involvement — generally a less severe disease course than pemphigus vulgaris

Management

• Both conditions require biopsy (including direct immunofluorescence) for definitive diagnosis — this is specialist referral territory, but recognising the pattern in OPD and referring promptly, rather than treating empirically as an infection or a drug reaction, is what changes the outcome
• Systemic corticosteroids are the mainstay of initial treatment for both, often alongside a steroid-sparing immunosuppressant for longer-term control, managed jointly with dermatology

Management

• Build a personal referral threshold for: suspected SJS/TEN, necrotising soft tissue infection, ophthalmic zoster, any lesion meeting ABCDE criteria or otherwise atypical/changing, suspected autoimmune blistering disease, and any systemically unwell patient
• Safety-netting language for the patient: clear instructions on what symptoms should bring them back immediately, not at the next routine visit

Clinical Recognition

• Intrinsic ageing (chronological, genetic) vs extrinsic ageing (photoageing, smoking, pollution) — the distinction shapes counselling and treatment choice
• Glogau photoageing scale as a quick, practical grading framework to anchor intervention discussions: Type I (mild — no wrinkles, early photoageing), Type II (moderate — wrinkles in motion, early lentigines), Type III (advanced — wrinkles at rest, visible telangiectasia, dyschromia), Type IV (severe — wrinkles throughout, no normal skin colour, prior skin cancers)
• Matching intervention intensity to grade prevents both under-treating a genuinely advanced case with topicals alone, and over-treating a mild case with unnecessarily aggressive procedures

Clinical Recognition

• Indications: dynamic wrinkles (glabellar frown lines, horizontal forehead lines, crow's feet), select therapeutic uses (axillary/palmar hyperhidrosis, masseter hypertrophy for facial slimming and bruxism) — know the indication before the technique
• Products available in Pakistan: onabotulinumtoxinA (Botox), abobotulinumtoxinA (Dysport), incobotulinumtoxinA (Xeomin), and several regional brands (Neuronox, Botulift) at a lower price point — dosing UNITS are NOT interchangeable between brands, and this is a genuinely common source of dosing error when switching products

Management — Exact Dosing Blueprint by Zone (onabotulinumtoxinA units)

• Onset of visible effect: 3-7 days, with full effect at 2 weeks — always schedule the review appointment at 2 weeks, not before, since touch-ups assessed too early lead to unnecessary re-treatment
• Duration: typically 3-4 months for facial dosing, longer for hyperhidrosis

Clinical Recognition

• Categories: hyaluronic acid (most common, reversible) vs other biostimulatory or semi-permanent agents — reversibility is a key patient-safety and counselling point
• Indications by facial zone: volume loss (cheeks, temples), lip enhancement, nasolabial folds, marionette lines, jawline contouring

Management — Product Selection by Zone

• Hyaluronic acid (HA): selected by viscosity/G-prime for the zone — a lower-viscosity, softer HA for lips and the tear trough; a higher-viscosity, more structural HA for cheek and jawline volumising. The genuine safety advantage of HA fillers is reversibility with hyaluronidase, which is exactly why they remain first-line for most indications in a general aesthetic practice.
• Calcium hydroxylapatite (CaHA): provides both immediate volume and a genuine biostimulatory collagen effect over subsequent months — well suited to the jawline and hands, but NOT reversible with hyaluronidase, which matters directly for complication management.
• Poly-L-lactic acid (PLLA): purely biostimulatory with no immediate volumising effect — results build gradually across 2-3 sessions over months as the body lays down new collagen, and this timeline needs to be set clearly at consultation so a patient doesn't judge the outcome after session one.
• Permanent fillers: not recommended — the complication profile (chronic granuloma formation, migration, and the simple fact that a complication cannot be reversed years later) outweighs the appeal of a 'one-time' treatment.
• Cannula technique is preferred over a sharp needle in higher-risk vascular zones (tear trough, temple, nose) given its comparatively lower vascular injury risk, though it does not eliminate that risk entirely

Clinical Recognition

• A genuinely distinct category from volumising filler — the goal here is skin QUALITY (hydration, elasticity, fine textural improvement), not shape or volume change, and this distinction is the single most important thing to get across to a patient who may arrive expecting filler-like results
• Skin boosters (Profhilo, Restylane Vital/Skinbooster range) use non-cross-linked or minimally cross-linked hyaluronic acid, injected superficially in a grid of small bolus points or micro-droplets rather than the linear threading or deeper bolus technique used for volumising filler
• Mesotherapy uses a broader cocktail — typically combinations of hyaluronic acid, vitamins, amino acids, and antioxidants — delivered via multiple superficial micro-injections across the treatment area

Management

• Standard course: 2-3 sessions spaced 3-4 weeks apart for the initial series, with maintenance sessions every 6-9 months thereafter
• Common treatment areas: face, neck, décolletage, and backs of the hands — areas where skin quality/laxity is the primary concern rather than volume loss
• Can be combined with volumising filler in the same treatment plan — skin boosters address surface quality while structural filler addresses volume, and these are complementary, not competing, treatments

Clinical Recognition

• Autologous, growth-factor-rich plasma prepared from the patient's own blood — genuinely low allergic/rejection risk given the autologous source
• Two primary aesthetic indications: facial skin rejuvenation (often combined with microneedling for delivery) and androgenetic alopecia (as an adjunct to topical/oral medical therapy, not a replacement for it)

Management — The Full Protocol

• Preparation: draw 10-20mL of venous blood into citrate tubes; centrifuge (a single-spin protocol is standard for most in-office systems; some protocols use a double spin for a more concentrated platelet yield) to separate and concentrate the platelet-rich plasma fraction from red cells and platelet-poor plasma
• Facial delivery: apply via microneedling (typically 0.5-1.5mm depth depending on the zone and indication) immediately after PRP application, allowing the growth factors direct access to the dermis; alternatively, fine-needle micro-injection across the treatment area
• Facial protocol: 3-4 sessions at 4-week intervals for the initial course, with a maintenance session every 6-12 months
• Scalp/hair protocol: injected directly into the scalp at the level of the dermis across the affected area, 3-4 sessions at 4-6 week intervals initially, then maintenance every 4-6 months — set expectations that visible improvement in shedding typically takes 3-4 months, and improvement in density takes longer still

Clinical Recognition

• Classification: superficial (glycolic, salicylic, mandelic), medium (TCA), deep (phenol) — depth determines indication, downtime, and risk

Management — The Exact Blueprint

Clinical Recognition

• Indications: acne scarring, mild skin laxity, overall skin texture/rejuvenation, often combined with topical actives or PRP

Management

• Standard microneedling: needle depth adjusted by indication and site — 0.5mm for product delivery/superficial texture, up to 1.5-2.5mm for acne scarring on thicker skin (avoiding thinner areas like the tear trough at these deeper settings)
• Course: 4-6 sessions at 3-4 week intervals for scarring or textural indications
• RF (radiofrequency) microneedling (e.g. Morpheus8, Genius): combines mechanical needling with radiofrequency energy delivered at the needle tip, achieving deeper, more controlled dermal heating than needling alone — genuinely better suited to skin laxity and deeper acne scarring than standard microneedling, at a correspondingly higher cost and typically fewer sessions needed (3-4)
• Combining with topical PRP or growth-factor serums applied immediately post-procedure takes advantage of the temporarily increased permeability from the micro-channels created

Clinical Recognition — Matching Device to Target

• Every laser/light decision starts with the same question: what is the target chromophore — melanin (pigment), haemoglobin (vessels), or water (for ablative resurfacing) — and what is the patient's Fitzpatrick type? Getting this pairing wrong is the single most common cause of laser complications in general aesthetic practice.

Management — Device Selection Blueprint

• A test patch before full treatment is genuinely worth the extra visit for any new patient on an ablative or aggressive setting, particularly Fitzpatrick IV and above
• Eye protection is mandatory for the patient, the operator, and everyone else in the room, without exception, for any laser device

Clinical Recognition

• Two functionally distinct categories: mono threads (smooth, no barbs) stimulate collagen and improve skin quality WITHOUT a mechanical lifting effect; cog/barbed threads anchor into tissue and provide a genuine, if temporary, mechanical lift

Management

• Indications: jawline definition, brow lift, and lower face/jowl laxity for cog threads; overall skin quality and fine line improvement for mono threads, often used in combination with cog threads in the same treatment
• Technique: careful vector planning before insertion — threads placed against the natural direction of tissue descent, entry points chosen to allow the anchoring barbs to engage the correct tissue plane
• Realistic duration: mechanical lift effect from cog threads typically lasts about 6-12 months as the PDO material absorbs, though the collagen-stimulating effect can leave some lasting textural benefit beyond that
• Complications to counsel on and recognise: visible dimpling or puckering at entry points, thread extrusion (particularly in thin-skinned areas), asymmetry, and infection at entry sites

Clinical Recognition

• Hypertrophic scar: raised, but stays WITHIN the original wound margins; can genuinely improve gradually over 12-18 months without intervention
• Keloid: extends BEYOND the original wound margins into surrounding normal skin; does not spontaneously regress; genuine genetic predisposition, more common in darker skin types and at specific sites — the ear lobe, chest, shoulders, and jawline are classic locations

Management — The Exact Blueprint

• First-line for both: intralesional triamcinolone acetonide, 10-40mg/mL depending on lesion size and firmness, injected directly into the scar at 4-6 week intervals — this is genuinely effective as monotherapy for many hypertrophic scars and smaller keloids
• Adjuncts: silicone gel sheeting or topical silicone gel used consistently for a minimum of 2-3 months, and pressure therapy (particularly effective and well-established for ear keloids using pressure earrings/clips)
• Resistant lesions: intralesional 5-fluorouracil, often combined with triamcinolone in the same syringe, as a second-line escalation
• Surgical excision: NEVER as monotherapy for keloids given a genuinely high recurrence rate (often described as higher than the original lesion) — excision must always be combined with adjuvant treatment such as immediate post-operative intralesional steroid, radiotherapy in select high-risk cases, or pressure therapy
• Pulsed dye laser can improve the residual redness and vascularity of a treated scar as a final cosmetic step, once the bulk of the lesion has been addressed

Management

• Case-based walkthroughs: sequencing multiple interventions (e.g. melasma plus photoageing, acne scarring plus volume loss, hair loss plus early androgenetic changes)
• Build a simple decision framework: diagnose, prioritise the patient's main concern, sequence treatments by risk/downtime, then review and adjust
• General sequencing principle: address active disease before cosmetic concerns built on top of it (control acne before treating its scars, control melasma activity before aggressive resurfacing), and sequence higher-downtime procedures first in a multi-treatment plan so the patient isn't managing two recovery periods at once

Clinical Recognition

• Revisit and consolidate red flags across all procedures: vascular occlusion (fillers), unexpected pain/blistering (lasers/peels), infection, nodule/granuloma formation, allergic reaction

Management — The Rehearsed Response

Patient Counselling

• Sunscreen selection for South Asian/darker skin: broad-spectrum, cosmetically elegant formulations patients will actually use daily — adherence beats theoretical SPF number
• Reapplication counselling, not just initial application — this is where most patients fall short
• Tie photoprotection explicitly back to whatever the patient is being treated for — melasma, PIH, post-peel or post-laser care, general anti-ageing — since patients treat sunscreen as optional far less often once they understand it's protecting the specific investment they just made

Patient Counselling

• Informed consent essentials: benefits, realistic outcomes, alternatives, and the honest complication profile — every time, for every procedure
• Expectation-setting script: anchor the conversation in 'improvement,' not 'perfection'
• Handling the dissatisfied patient: listen first, validate the concern, re-examine objectively, and offer a clear next step rather than getting defensive
• Ethical and practice considerations: avoid over-promising on social-media-driven requests, and know your own scope and referral threshold

Frequently Asked Patient Questions

• "Is this permanent?" — Almost nothing in aesthetic medicine is; build the honest duration into every consultation rather than answering this reactively when asked
• "Why does the same treatment cost different amounts at different clinics?" — Product brand, practitioner experience, and genuine quantity used all vary; encourage patients to ask specifically what product and how much is being used, not just compare a headline price
• "Can I combine two treatments on the same day?" — Genuinely depends on the pairing; some combinations are routine (Botox and filler together), others need spacing (an aggressive laser and a chemical peel on the same visit is generally not advisable)
• "Will this work as well as it did for my friend, or on social media?" — Individual skin type, ageing pattern, and the specific concern all affect outcome; avoid comparing patients to each other in your own counselling, since it sets an expectation you can't actually control
• "How do I know if my doctor or clinic is legitimate?" — A worthwhile question to welcome, not deflect; genuine practitioners should be transparent about training, product sourcing, and complication protocols

Management

• Start with what you can deliver safely and confidently today — a solid medical dermatology OPD with a small, well-chosen aesthetic menu (Botox, a core filler range, and one resurfacing option) outperforms an ambitious menu delivered without genuine confidence in every item on it
• Build genuine before/after documentation from day one, with patient consent — this becomes both a clinical record and, over time, your most credible marketing asset
• Referral relationships work both ways: build a relationship with a dermatologist or plastic surgeon for complications and cases outside your scope, and be the clinician other specialties refer their patients' skin concerns to
• Price consistently and transparently — a patient who feels a price was improvised in the room trusts the treatment recommendation less, even when the price itself is fair
• Continue structured learning beyond this course — techniques and products in aesthetic medicine genuinely evolve, and treating this week as a finish line rather than a foundation is a common and avoidable mistake

That closes the seven days. The thread running through all of it has been the same: recognise accurately, treat with an exact and appropriate blueprint, counsel honestly, and know precisely where your own scope ends. That combination, not any single technique, is what actually builds a dermatology-aesthetics practice patients trust and return to.